HMPL-309
- Generic Name
- HMPL-309
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 24
- Registration Number
- NCT02601248
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 33
- Registration Number
- NCT02601274
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun-Yat-sen univercity cancer centre, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath